Prognostic Value of a New Marker, IBI Score and NLR Change in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors (Prognostic value of IBI score and NLR change in NSCLC)

Melek Özdemir; Gamze Gokoz Dogu; Burcu Yapar Taşköylü; Atike Gökçen Demiray; Serkan Değirmencioğlu; Arzu Yaren; Burçin Çakan Demirel; Tolga Doğan; Taliha Güçlü Kantar; Semra Taş; Bedriye Açıkgöz Yıldız; Gamze Serin Özel; Ceren Mordağ Çiçek

Makale detayları

Prognostic Value of a New Marker, IBI Score and NLR Change in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors (Prognostic value of IBI score and NLR change in NSCLC)

Yazarlar:

Melek Özdemir | Gamze Gokoz Dogu | Burcu Yapar Taşköylü | Atike Gökçen Demiray | Serkan Değirmencioğlu | Arzu Yaren | Burçin Çakan Demirel | Tolga Doğan | Taliha Güçlü Kantar | Semra Taş | Bedriye Açıkgöz Yıldız | Gamze Serin Özel | Ceren Mordağ Çiçek

Yayıncı:

Mugla Sitki Kocman University

Ana Başlıklar:

İç Hastalıkları

Dergi:

Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi Vol.12 Issue 2, pp.91-98

Belge Tipi:

Makale

Yayın Tarihi:

8/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001357182

pISSN:

2148-8118

Anahtar kelimeler:

Özet:

 This study aims to investigate the prognostic value of IBI score inflammatory benchmark index and NLR neutrophil lymphocyte ratio change during treatment for overall survival OS and progression-free survival PFS in nonsmall cell lung cancer NSCLC patients. A total of 155 NSCLC patients without driver mutations who were treated with immune checkpoint inhibitor ICI were included in the study. Laboratory and clinical parameters evaluated at the beginning and third month of ICI treatment were retrospectively recorded. The prognostic value of IBI score, NLR ratio and NLR change values were analysed using CRP, neutrophil, lymphocyte and platelet values. The median follow-up period was 26 months. Chemotherapy and ICI status of the patients were recorded. Regardless of the stage of immunotherapy, 34.8 of the patients 54 patients did not progress after ICI. 101 patients 65.2 progressed after ICI. The increase in mortality was significant when NLR10.25 p0.001 and NLR Change3.60 p0.001. Age p0.021, ECOG performance p0.043, stage at diagnosis p0.013, NLR change p0.001 and NLR p0.001 were significantly associated with mOS. Age p0.013, stage at diagnosis p0.004, IBI score p0.027, NLR change p0.001 and NLR p0.002 were prognostic for PFS. All these results suggest that IBI score and NLR change can be used as prognostic markers for ICI treatment response in NSCLC patients.

 This study aims to investigate the prognostic value of IBI score inflammatory benchmark index and NLR neutrophil lymphocyte ratio change during treatment for overall survival OS and progression-free survival PFS in nonsmall cell lung cancer NSCLC patients. A total of 155 NSCLC patients without driver mutations who were treated with immune checkpoint inhibitor ICI were included in the study. Laboratory and clinical parameters evaluated at the beginning and third month of ICI treatment were retrospectively recorded. The prognostic value of IBI score, NLR ratio and NLR change values were analysed using CRP, neutrophil, lymphocyte and platelet values. The median follow-up period was 26 months. Chemotherapy and ICI status of the patients were recorded. Regardless of the stage of immunotherapy, 34.8 of the patients 54 patients did not progress after ICI. 101 patients 65.2 progressed after ICI. The increase in mortality was significant when NLR10.25 p0.001 and NLR Change3.60 p0.001. Age p0.021, ECOG performance p0.043, stage at diagnosis p0.013, NLR change p0.001 and NLR p0.001 were significantly associated with mOS. Age p0.013, stage at diagnosis p0.004, IBI score p0.027, NLR change p0.001 and NLR p0.002 were prognostic for PFS. All these results suggest that IBI score and NLR change can be used as prognostic markers for ICI treatment response in NSCLC patients.

 This study aims to investigate the prognostic value of IBI score inflammatory benchmark index and NLR neutrophil lymphocyte ratio change during treatment for overall survival OS and progression-free survival PFS in nonsmall cell lung cancer NSCLC patients. A total of 155 NSCLC patients without driver mutations who were treated with immune checkpoint inhibitor ICI were included in the study. Laboratory and clinical parameters evaluated at the beginning and third month of ICI treatment were retrospectively recorded. The prognostic value of IBI score, NLR ratio and NLR change values were analysed using CRP, neutrophil, lymphocyte and platelet values. The median follow-up period was 26 months. Chemotherapy and ICI status of the patients were recorded. Regardless of the stage of immunotherapy, 34.8 of the patients 54 patients did not progress after ICI. 101 patients 65.2 progressed after ICI. The increase in mortality was significant when NLR10.25 p0.001 and NLR Change3.60 p0.001. Age p0.021, ECOG performance p0.043, stage at diagnosis p0.013, NLR change p0.001 and NLR p0.001 were significantly associated with mOS. Age p0.013, stage at diagnosis p0.004, IBI score p0.027, NLR change p0.001 and NLR p0.002 were prognostic for PFS. All these results suggest that IBI score and NLR change can be used as prognostic markers for ICI treatment response in NSCLC patients.

 Bu çalışma, IBI skoru inflamatuar ben chmark index ve tedavi sırasındaki NLR nötrofil lenfosit oranı değişiminin nonsmall cell lung cancer NSCLC hastalarında genel sağkalım OS ve progresyonsuz sağkalım PFS için prognostik değerini araştırmayı amaçlamaktadır. Driver mutasyonu olmayan ve tedavi basamaklarında immün kontrol noktası inhibitörü ICI uygulanan 155 NSCLC tanılı hasta çalışmaya alındı. ICI tedavi başlangıcında ve tedavinin üçüncü ayında değerlendirilen laboratuvar ve klinik parametreler retrospektif olarak kaydedildi. CRP, nötrofil, lenfosit ve trombosit değeri kullanılarak; IBI skor, NLR oranı ve NLR change değerlerinin prognostik değeri analiz edildi. Ortalama takip süresi 26.07 aydı. Hastaların kemoterapi ve ICI alma durumları kaydedildi. İmmünoterapiyi kaçıncı basamakta alırsa alsın, ICI sonrası hastaların 34.8inde 54 hasta progresyon görülmedi. 101 hasta 65.2 ise ICI sonrası progrese oldu. NLR10.25 p0.001 ve NLR Change3.60 p0.001 olduğunda mortalitedeki artış anlamlı bulundu. Yaş p0.021, ECOG performans p0.043, tanıdaki evre p0.013, NLR change p0.001 ve NLR p0.001 ile mOS arasındaki ilişki anlamlı bulundu. Yaş p0.013, tanıdaki evre p0.004, IBI skor p0.027, NLR change p0.001 ve NLR p0.002 PFS için prognostik olduğu bulundu. Tüm bu sonuçlar IBI skor ve NLR changein NSCLC hastalarında ICI tedavi yanıtı için prognostik belirteç olarak kullanılabileceğini düşündürmektedir.

Makale detayları

Prognostic Value of a New Marker, IBI Score and NLR Change in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors (Prognostic value of IBI score and NLR change in NSCLC)

Yazarlar:

Melek Özdemir | Gamze Gokoz Dogu | Burcu Yapar Taşköylü | Atike Gökçen Demiray | Serkan Değirmencioğlu | Arzu Yaren | Burçin Çakan Demirel | Tolga Doğan | Taliha Güçlü Kantar | Semra Taş | Bedriye Açıkgöz Yıldız | Gamze Serin Özel | Ceren Mordağ Çiçek

Yayıncı:

Mugla Sitki Kocman University

Ana Başlıklar:

İç Hastalıkları

Dergi:

Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi Vol.12 Issue 2, pp.91-98

Belge Tipi:

Makale

Yayın Tarihi:

8/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001357182

pISSN:

2148-8118

IBI Score

NLR Change

NSCLCIBI Skor

NLR Değişimi

NSCLC

Sayı

Makale detayları

Prognostic Value of a New Marker, IBI Score and NLR Change in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors (Prognostic value of IBI score and NLR change in NSCLC)

Yazarlar: Melek Özdemir | Gamze Gokoz Dogu | Burcu Yapar Taşköylü | Atike Gökçen Demiray | Serkan Değirmencioğlu | Arzu Yaren | Burçin Çakan Demirel | Tolga Doğan | Taliha Güçlü Kantar | Semra Taş | Bedriye Açıkgöz Yıldız | Gamze Serin Özel | Ceren Mordağ Çiçek

Yayıncı: Mugla Sitki Kocman University

Ana Başlıklar: İç Hastalıkları

Dergi: Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi Vol.12 Issue 2, pp.91-98

Belge Tipi: Makale

Yayın Tarihi: 8/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001357182

pISSN: 2148-8118

IBI Score

NLR Change

NSCLCIBI Skor

NLR Değişimi

NSCLC

Sayı

Yazarlar:

Melek Özdemir | Gamze Gokoz Dogu | Burcu Yapar Taşköylü | Atike Gökçen Demiray | Serkan Değirmencioğlu | Arzu Yaren | Burçin Çakan Demirel | Tolga Doğan | Taliha Güçlü Kantar | Semra Taş | Bedriye Açıkgöz Yıldız | Gamze Serin Özel | Ceren Mordağ Çiçek

Yayıncı:

Mugla Sitki Kocman University

Ana Başlıklar:

İç Hastalıkları

Dergi:

Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi Vol.12 Issue 2, pp.91-98

Belge Tipi:

Makale

Yayın Tarihi:

8/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001357182

pISSN:

2148-8118